Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ECE1 | P42892 | 3/20 | 0.58 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.43 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.43 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.43 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.43 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.43 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | FAAH | O00519 | 2/20 | 0.40 |
| ▸ | CNR1 | P21554 | 2/20 | 0.40 |
| ▸ | CNR2 | P34972 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23768536 | 0.91 | ECE1 (0.50) | ECE1HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL8735106 | 0.86 | ATM (0.52) | ECE1HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL10897119 | 0.84 | PRMT1 (0.59) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL23567470 | 0.82 | PRMT1 (0.63) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL23567380 | 0.82 | PRMT1 (0.63) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL3267882 | 0.82 | PRMT1 (0.63) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| Succinimide SCHEMBL28352922 | 0.82 | ECE1 (0.42) | ECE1HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL9717468 | 0.81 | ECE1 (0.81) | ECE1TSHRFAAHCNR1CNR2 | |
| SCHEMBL9717431 | 0.81 | ECE1 (0.65) | ECE1FAAHCNR1CNR2LMNA | |
| SCHEMBL10866810 | 0.81 | HDAC3 (0.41) | ECE1HDAC3HDAC4HDAC1HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 243 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10953073-B2 | XTEN conjugate compositions and methods of making same | AMUNIX PHARMACEUTICALS, INC. (US) | 2021-03-23 | — | — | US | claimed |
| EP-2804631-B1 | SURROBODY CONJUGATES | I2 PHARMACEUTICALS INC (US) | 2021-03-17 | — | — | EP | claimed |
| EP-2675480-B1 | METHODS OF PREPARATION OF CONJUGATES | IMMUNOGEN INC (US) | 2018-12-26 | — | — | EP | claimed |
| US-20180104349-A9 | Novel linker, preparation method, and application thereof | QIN GANG (CN) | 2018-04-19 | — | — | US | claimed |
| EP-2494075-B1 | TEMPLATED NANOCONJUGATES | UNIV NORTHWESTERN (US) | 2018-04-04 | — | — | EP | claimed |
| CN-107050468-A | The preparation method of conjugate | 伊缪诺金公司 | 2017-08-18 | — | — | CN | claimed |
| EP-2249873-B1 | CONJUGATED MOLECULES COMPRISING A PEPTIDE DERIVED FROM THE CD4 RECEPTOR COUPLED TO A POLYANION FOR THE TREATMENT OF AIDS | PASTEUR INSTITUT (FR) | 2016-11-16 | — | — | EP | claimed |
| US-20160193355-A1 | Novel linker, preparation method, and application thereof | QIN GANG (CN) | 2016-07-07 | — | — | US | claimed |
| EP-2399609-B1 | Process for preparing maytansinoid antibody conjugates | IMMUNOGEN INC (US) | 2015-03-18 | — | — | EP | claimed |
| EP-2478049-B1 | A POLYMER SUPPORT | UNIV CAPE TOWN (ZA) | 2015-02-25 | — | — | EP | claimed |
| EP-2032172-B1 | LEPTOMYCIN DERIVATIVES | SANOFI SA (FR) | 2012-06-06 | — | — | EP | claimed |
| EP-1813614-B1 | Cytotoxic agents comprising new tomaymycin derivatives | SANOFI SA (FR) | 2011-10-05 | — | — | EP | claimed |
| EP-0590038-B1 | AMINO ACID DERIVATIVE AND BROMOACETYL MODIFIED PEPTIDES | US HEALTH (US) | 1998-04-01 | — | — | EP | claimed |
| EP-0590038-A1 | AMINO ACID DERIVATIVE AND BROMOACETYL MODIFIED PEPTIDES | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1994-04-06 | — | — | EP | claimed |
| US-5286846-A | Trifunctional reagents for solid phase synthesis | THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPT. OF HEALTH AND HUMAN SERVICES (US) | 1994-02-15 | — | — | US | claimed |
| CN-114173812-B | Heterologous administration of Tau vaccine | Janssen Pharmaceuticals, Inc. (US) | 2026-05-26 | — | — | CN | disclosed |
| US-20260124312-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR EPHA2 | BICYCLETX LIMITED (GB) | 2026-05-07 | — | — | US | disclosed |
| WO-1992022318-A1 | AMINO ACID DERIVATIVE AND BROMOACETYL MODIFIED PEPTIDES | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by the DEPARTEMENT OF HEALTH AND HUMAN SERVICES (US) | 1992-12-23 | — | — | WO | disclosed |
| US-4328311-A | USEFUL IN IMMUNOASSAY | SYVA COMPANY (US) | 1982-05-04 | — | — | US | disclosed |
| US-4220722-A | ACYLATION, AMIDATION, SULFIDING | SYVA COMPANY (US) | 1980-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160193355-A1 | Novel linker, preparation method, and application thereof | ENGASE, SORT1, DNPEP | ECE1 880/4885HDAC3 1100/4885HDAC4 1561/4885 |
| US-10953073-B2 | XTEN conjugate compositions and methods of making same | XPA, TXLNA, NGLY1 | ECE1 1376/4885HDAC3 3658/4885HDAC4 3292/4885 |
| US-20180104349-A9 | Novel linker, preparation method, and application thereof | ENGASE, SORT1, DNPEP | ECE1 880/4885HDAC3 1100/4885HDAC4 1561/4885 |
| US-20260124312-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR EPHA2 | EPHA2, EPHB2, ERBB2 | ECE1 332/4885HDAC3 4684/4885HDAC4 4697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.